PTC Therapeutics, Inc.
$72.32
▼
-1.43%
2026-04-21 08:59:00
www.ptcbio.com
NMS: PTCT
Explore PTC Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.95 B
Current Price
$72.32
52W High / Low
$87.5 / $35.95
Stock P/E
8.72
Book Value
$-2.52
Dividend Yield
—
ROCE
44.37%
ROE
-104.75%
Face Value
—
EPS
$8.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
991
Beta
0.55
Debt / Equity
-13.19
Current Ratio
2.35
Quick Ratio
2.27
Forward P/E
28.27
Price / Sales
3.29
Enterprise Value
$6.45 B
EV / EBITDA
7.2
EV / Revenue
3.73
Rating
Buy
Target Price
$87.87
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Enliven Therapeutics, Inc. | $46.41 | — | $2.88 B | — | -26.04% | -26.95% | $48.53 / $14.79 | $7.73 |
| 2. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
| 3. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 4. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 5. | Silence Therapeutics plc | $7.93 | — | $349.74 M | — | -76.17% | -90.27% | $2.6 / $0.5 | $1.32 |
| 6. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 7. | Terns Pharmaceuticals, Inc. | $52.74 | — | $6.09 B | — | -10.92% | -14.23% | $53.19 / $2.23 | $8.96 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 164.68 M | 211.01 M | 178.88 M | 1.18 B | 213.17 M |
| Operating Profit | -81.62 M | 3.49 M | -34.86 M | 969.5 M | -15.87 M |
| Net Profit | -134.97 M | 15.9 M | -64.85 M | 866.56 M | -65.89 M |
| EPS in Rs | -1.63 | 0.19 | -0.78 | 10.47 | -0.8 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.73 B | 806.78 M | 937.82 M | 698.8 M |
| Operating Profit | 856.51 M | -146.75 M | -349.4 M | -439.93 M |
| Net Profit | 682.64 M | -363.3 M | -626.6 M | -559.02 M |
| EPS in Rs | 8.25 | -4.39 | -7.57 | -6.75 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.9 B | 1.71 B | 1.9 B | 1.71 B |
| Total Liabilities | 3.1 B | 2.8 B | 2.71 B | 2.05 B |
| Equity | -205.31 M | -1.1 B | -818.55 M | -347.09 M |
| Current Assets | 2.27 B | 1.37 B | 1.22 B | 693.78 M |
| Current Liabilities | 968.43 M | 580.98 M | 603.1 M | 406.24 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 711.2 M | -107.69 M | -158.42 M | -356.65 M |
| Investing CF | -861.98 M | 44.18 M | -176.74 M | 290.18 M |
| Financing CF | 331.09 M | 255.87 M | 646.4 M | 167.95 M |
| Free CF | 411.18 M | -181.94 M | -279.04 M | -509.11 M |
| Capex | -300.01 M | -74.25 M | -120.62 M | -152.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 114.51% | -13.97% | 34.2% | — |
| Earnings Growth % | 287.9% | 42.02% | -12.09% | — |
| Profit Margin % | 39.44% | -45.03% | -66.81% | -80% |
| Operating Margin % | 49.49% | -18.19% | -37.26% | -62.95% |
| Gross Margin % | 97.28% | 92.89% | 93.02% | 93.61% |
| EBITDA Margin % | 51.29% | -14.93% | -35.22% | -52.63% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.